Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
N/A(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05405322Active Not Recruiting

Improving Care and Community Representation for Adolescents and Young Adults Living With HIV in West Africa

Role: collaborator

NCT03101852Not ApplicableCompleted

Nutritional Rehabilitation in Senegalese HIV-infected Children and Adolescents

Role: collaborator

NCT03191175Completed

Inflammasome Activation Via Circulating Metabolites

Role: collaborator

NCT02889094Unknown

French HIV-HBV Cohort

Role: collaborator

NCT01874743Phase 2Unknown

Rosuvastatin to Decrease Residual Immune Activation in HIV Infection

Role: collaborator

NCT00970879Phase 3Completed

Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

Role: collaborator

NCT00821847Completed

Renal Function Assessment in HIV Patient

Role: collaborator

All 7 trials loaded